Myocardial Inflammation Recruiting Phase 4 Trials for Dapagliflozin (DB06292)

IndicationStatusPhase
DBCOND0088874 (Myocardial Inflammation)Recruiting4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03782259Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2Screening